Zonsen PepLib Enters Peptide Drug Discovery Collaboration with Lilly

Zonsen PepLib Biotech has entered into a global research collaboration and licence agreement with Eli Lilly to discover and develop novel peptide drug candidates. Under the agreement, PepLib will use its proprietary, diversified peptide library and discovery platform to identify and optimise lead molecules. Eli Lilly will then be responsible for subsequent investigational new drug (IND)-enabling studies, clinical development and commercialisation. PepLib will receive an upfront payment and is eligible for future development, regulatory and sales milestone payments, plus tiered royalties.

This deal with Lilly follows closely on the heels of another major partnership for PepLib. In January 2026, the company licensed the global rights to an undisclosed peptide-based radioligand therapy asset to Novartis. These consecutive collaborations with leading pharmaceutical firms validate PepLib's peptide discovery platform and its strategy of leveraging external partnerships to advance its technology.

According to PharmCube's NextBiopharm® database, this is China's sixth peptide outlicensing deal with a Big Pharma company. Click here to request a free trial for NextBiopharm®.

Daily News
BMS Oral Protein Degrader Shows Positive Phase III Results in Myeloma
2026-03-13
Lilly Issues Safety Warning on Compounded Tirzepatide + Vitamin B12
2026-03-13
Lilly Announces USD 3b Investment in China to Bolster Local Supply Chain
2026-03-12
UCB's Bimekizumab Demonstrates Superiority to Risankizumab in PsA
2026-03-12
Laekna's ActRIIA Inhibitor Shows Promising Muscle Gain, Fat Loss
2026-03-11
Latest Report
Global Drug Progress Report during January 2026
Details